TREX1 Modulators Resolve Immune Autoimmunity Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer and viral infections face limitations in effectively modulating the immune response, particularly in harnessing the innate immune system's recognition of non-self DNA patterns, as excessive type I interferon production can be harmful and induce autoimmunity, necessitating the development of targeted compounds to regulate the cGAS/STING pathway and TREX1 activity.
Innovation Solution
Development of compounds with specific chemical structures that modulate the activity of TREX1, a 3'-5' DNA exonuclease, to inhibit its function, thereby regulating the cGAS/STING pathway and type I interferon production, which are useful in treating various cancers and potentially viral infections by enhancing anti-tumor and antiviral immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TREX1 is inhibited to enhance innate immune response and type I interferon production, then anti-tumor and antiviral immunity is improved, but excessive type I interferon production can induce autoimmunity and harm the host
Solution Approach 1:
The patent applies parameter changes by developing compounds that specifically modulate TREX1 enzymatic activity parameters. The compounds alter the kinetic parameters of TREX1 (such as kcat and Km) to achieve selective inhibition, thereby controlling the balance between immune activation and autoimmunity prevention. This allows precise regulation of type I interferon production without complete blockade, resolving the contradiction between effective immune response and autoimmunity risk.
Solution Approach 2:
The patent introduces intermediary compounds as mediators between the cGAS/STING pathway and TREX1. These compounds act as selective modulators that interfere with the direct interaction between cytosolic DNA and TREX1, thereby controlling the amplification loop. The intermediaries enable fine-tuned regulation of the immune response, allowing beneficial immune activation while preventing excessive interferon production that would cause autoimmunity.
2Productivity
If type I interferon production is increased to activate innate and adaptive immunity, then cancer treatment effectiveness is improved, but harmful effects and autoimmunity occur
Solution Approach 1:
The patent applies partial action by developing TREX1 modulators that provide just enough inhibition to achieve therapeutic benefit without complete blockade. The compounds create a partial inhibition state that is sufficient to enhance immune response and activate anti-tumor immunity, but not so strong as to cause complete immunosuppression or excessive interferon accumulation. This partial action approach resolves the contradiction between immune activation capacity and harmful effects.
Solution Approach 2:
The patent implements feedback mechanisms through the development of compounds that respond to the cellular state. The TREX1 modulators are designed to provide feedback regulation, where the degree of TREX1 inhibition is dynamically adjusted based on the cellular context and interferon production levels. This feedback control ensures that immune activation is proportional to the actual need, preventing excessive interferon production while maintaining therapeutic effectiveness.
3Reliability
If TREX1 activity is reduced to prevent DNA degradation, then cancer cell survival is improved, but immune recognition and anti-tumor response are compromised
Solution Approach 1:
The patent applies parameter changes by selectively altering TREX1 kinetic parameters in a controlled manner. The compounds modify specific parameters such as catalytic efficiency (kcat) or substrate affinity (Km) to achieve the desired balance. By precisely controlling which parameters are changed and to what extent, the patent enables cancer cell survival while maintaining immune response regulation capability, resolving the contradiction between cell survival and immune response precision.
Solution Approach 2:
The patent applies local quality by creating selective inhibition at specific locations within the cell. The TREX1 modulators are designed to concentrate their effect at the cGAS/STING pathway interface, providing localized inhibition where it is most needed for immune activation, while leaving other TREX1 functions intact. This localized approach allows cancer cell survival to be maintained while achieving precise immune response regulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit TREX1 activity, potentially expanding the pool of patients responding to anti-tumor therapies and enhancing the effectiveness of anti-PD-1 therapy, while also inducing an innate antiviral immune response, thus addressing the challenges of immune activation and autoimmunity.
Implementation Method 1
Three prime repair exonuclease I (TREX1) is a 3′-5′ DNA exonuclease responsible for the removal of ectopically expressed ssDNA and dsDNA
Implementation Method 2
cGAS catalyzes the generation of the cyclic dinucleotide 2′,3′-cGAMP
Implementation Method 3
Type I interferons also bind their own receptors and activate interferon responsive genes that contribute to activation of cells involved in adaptive immunity
Data Source
AI summary
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with TREX1.